sildenafil + placebo

ApprovedCompleted

3 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Spinal Cord Injury

Conditions

Spinal Cord Injury, Erectile Dysfunction, Spinal Cord Trauma, Injuries, Spinal Cord, Impotence

Trial Timeline

Sep 1, 2002 → Aug 1, 2003

NCT ID

NCT00654082

About sildenafil + placebo

sildenafil + placebo is a approved stage product being developed by Pfizer for Spinal Cord Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT00654082. Target conditions include Spinal Cord Injury, Erectile Dysfunction, Spinal Cord Trauma.

What happened to similar drugs?

6 of 20 similar drugs in Spinal Cord Injury were approved

Approved (6) Terminated (1) Active (13)

🔄Ropivacaine + BupivacaineAstraZenecaPhase 3

🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3

✅Onasemnogene Abeparvovec-brveNovartisApproved

🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3

🔄onasemnogene abeparvovecNovartisPhase 3

🔄onasemnogene abeparvovec-xioiNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01616381	Phase 3	UNKNOWN	Mar 1, 2013	Dec 1, 2019	Heart Failure
NCT01726049	Phase 3	Completed	Oct 1, 2011	Dec 1, 2014	Heart Failure, Diastolic
NCT01334554	Phase 1/2	Completed	Apr 1, 2011	Aug 1, 2013	Metabolic Syndrome
NCT00644631	Approved	Completed	Jun 1, 2003	Apr 1, 2004	Erectile Dysfunction
NCT00648596	Approved	Completed	May 1, 2003	May 1, 2004	Erectile Dysfunction
NCT00654082	Approved	Completed	Sep 1, 2002	Aug 1, 2003	Spinal Cord Injury

Competing Products

20 competing products in Spinal Cord Injury

See all competitors

Product	Company	Stage	Hype Score
SUN13837 injection + Placebo	Daiichi Sankyo	Phase 2	35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg	Astellas Pharma	Phase 2	35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 2	42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 1	36
Elezanumab	AbbVie	Pre-clinical	30
Elezanumab + Placebo	AbbVie	Phase 2	35
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	40
Onasemnogene Abeparvovec-xioi	Novartis	Phase 1	21
Zolgensma	Novartis	Pre-clinical	33
BVS857 + Placebo	Novartis	Phase 2	35
AVXS-101	Novartis	Phase 1	29
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	44
Onasemnogene Abeparvovec-brve	Novartis	Approved	50
Onasemnogene Abeparvovec-xioi	Novartis	Pre-clinical	30
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	40
branaplam	Novartis	Phase 1/2	32
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	40
onasemnogene abeparvovec	Novartis	Phase 3	47
onasemnogene abeparvovec-xioi	Novartis	Phase 3	40
Risdiplam	Roche	Phase 1	29